| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Liu S, Zheng R, Zhang M, et al. Incidence and mortality of colorectal cancer in China, 2011[J]. Chin J Cancer Res, 2015, 27(1): 22-28.
|
| [3] |
Yoo SY, Bang SY, Jeong SN, et al. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer[J]. Oncotarget, 2016, 7(13): 16479-16489.
|
| [4] |
Nakatake M, Kuwano N, Kaitsurumaru E, et al. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment[J]. Mol Ther, 2021, 29(5): 1782-1793.
|
| [5] |
Deng L, Yang X, Fan J, et al. IL-24-armed oncolytic vaccinia virus exerts potent antitumor effects via multiple pathways in colorectal cancer[J]. Oncol Res, 2021, 28(6): 579-590.
|
| [6] |
Samson A, West EJ, Carmichael J, et al. Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients[J]. Cancer Immunol Res, 2022, 10(6): 745-756.
|
| [7] |
Downs-Canner S, Guo ZS, Ravindranathan R, et al. Phase 1 study of intravenous oncolytic Poxvirus (vvDD) in patients with advanced solid cancers[J]. Mol Ther, 2016, 24(8): 1492-1501.
|
| [8] |
Park SH, Breitbach CJ, Lee J, et al. Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer[J]. Mol Ther, 2015, 23(9): 1532-1540.
|
| [9] |
Xiao B, Zhang L, Liu H, et al. Oncolytic adenovirus CD55-Smad4 suppresses cell proliferation, metastasis, and tumor stemness in colorectal cancer by regulating Wnt/β-Catenin signaling pathway[J]. Biomedicines, 2020, 8(12): 593.
|
| [10] |
Guo Y, Zhang Z, Xu X, et al. Menstrual blood-derived stem cells as delivery vehicles for oncolytic adenovirus virotherapy for colorectal cancer[J]. Stem Cells Dev, 2019, 28(13): 882-896.
|
| [11] |
Gao H, Zhang X, Ding Y, et al. Synergistic suppression effect on tumor growth of colorectal cancer by combining radiotherapy with a trail-armed oncolytic adenovirus[J]. Technol Cancer Res Treat, 2019, 18: 1533033819853290.
|
| [12] |
Jessup JM, Kabbout M, Korokhov N, et al. Adenovirus and oxaliplatin cooperate as agnostic sensitizers for immunogenic cell death in colorectal carcinoma[J]. Hum Vaccin Immunother, 2020, 16(3): 636-644.
|
| [13] |
Fabian KP, Malamas AS, Padget MR, et al. Therapy of established tumors with rationally designed multiple agents targeting diverse immune-tumor interactions: engage, expand, enable[J]. Cancer Immunol Res, 2021, 9(2): 239-252.
|
| [14] |
Sun K, Xu Y, Zhang L, et al. A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer[J]. Clin Cancer Res, 2022, 28(20): 4392-4401.
|
| [15] |
Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma[J]. N Engl J Med, 2022, 386(26): 2471-2481.
|
| [16] |
Seiwert TY, Darga T, Haraf D, et al. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation[J]. Ann Oncol, 2013, 24(3): 769-776.
|
| [17] |
Freytag SO, Stricker H, Lu M, et al. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2014, 89(2): 268-276.
|
| [18] |
Palmer CD, Rappaport AR, Davis MJ, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results[J]. Nat Med, 2022, 28(8): 1619-1629.
|
| [19] |
Garcia-Carbonero R, Salazar R, Duran I, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection[J]. J Immunother Cancer, 2017, 5(1): 71.
|
| [20] |
Sze DY, Iagaru AH, Gambhir SS, et al. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography[J]. Hum Gene Ther, 2012, 23(1): 91-97.
|
| [21] |
Geevarghese SK, Geller DA, de Haan HA, et al. Phase Ⅰ/Ⅱ study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver[J]. Hum Gene Ther, 2010, 21(9): 1119-1128.
|
| [22] |
Zhang W, Zeng B, Hu X, et al. Oncolytic herpes simplex virus type 2 can effectively inhibit colorectal cancer liver metastasis by modulating the immune status in the tumor microenvironment and inducing specific antitumor immunity[J]. Hum Gene Ther, 2021, 32(3-4): 203-215.
|
| [23] |
Zhang W, Wang F, Hu X, et al. Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity[J]. Oncol Lett, 2019, 17(1): 815-822.
|
| [24] |
Haghighi-Najafabadi N, Roohvand F, Shams Nosrati MS, et al. Oncolytic herpes simplex virus type-1 expressing IL-12 efficiently replicates and kills human colorectal cancer cells[J]. Microb Pathog, 2021, 160: 105164.
|
| [25] |
Wu Z, Ichinose T, Naoe Y, et al. Combination of cetuximab and oncolytic virus canerpaturev synergistically inhibits human colorectal cancer growth[J]. Mol Ther Oncolytics, 2019, 13: 107-115.
|
| [26] |
Zhou X, Zhao J, Zhang JV, et al. Enhancing Therapeutic efficacy of oncolytic herpes simplex virus with MEK inhibitor trametinib in some BRAF or KRAS-mutated colorectal or lung carcinoma models[J]. Viruses, 2021, 13(9): 1758.
|
| [27] |
Shayan S, Arashkia A, Bahramali G, et al. Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia[J]. Cancer Cell Int, 2022, 22(1): 164.
|
| [28] |
王凤娇, 韩继武, 王大秀. 荷IL-12新城疫病毒治疗结肠癌的实验及其机制探讨[J].现代肿瘤医学, 2021, 29(5): 761-765.
|
| [29] |
Meng F, Cao Y, Su H, et al. Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model[J]. PLoS One, 2022, 17(4): e0264896.
|
| [30] |
Tian L, Liu T, Jiang S, et al. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy[J]. Gene Ther, 2023, 30(1-2): 64-74.
|
| [31] |
梁莹, 黄盼柳, 樊晓晖, 等. 新城疫病毒7793对结肠癌肝转移模型小鼠肝内Th1、Th2、Th17类细胞因子表达的影响[J]. 肿瘤学杂志, 2016, 22(5): 355-359.
|
| [32] |
古丽娜儿, 王思橦, 黄莉莉, 等.新城疫病毒诱导结肠癌Caco2细胞株发生Caspase和p38MAPK依赖性诱凋亡[J]. 同济大学学报(医学版), 2020, 41(5): 546-551.
|
| [33] |
Li Q, Wei D, Feng F, et al. α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus[J]. J Cancer Res Clin Oncol, 2017, 143(11): 2171-2181.
|
| [34] |
Schulze T, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial[J]. Cancer Immunol Immunother, 2009, 58(1): 61-69.
|
| [35] |
Sharifi N, Soleimanjahi H, Mokhtari-Dizaji M, et al. Low-intensity ultrasound as a novel strategy to improve the cytotoxic effect of oncolytic reovirus on colorectal cancer model cells[J]. Intervirology, 2022, 65(2): 110-118.
|
| [36] |
Babaei A, Soleimanjahi H, Soleimani M, et al. The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells[J]. Daru, 2020, 28(2): 555-565.
|
| [37] |
Jiffry J, Thavornwatanayong T, Rao D, et al. Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer[J]. Clin Cancer Res, 2021, 27(3): 865-876.
|
| [38] |
Maitra R, Seetharam R, Tesfa L, et al. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan[J]. Oncotarget, 2014, 5(9): 2807-2819.
|
| [39] |
Maitra R, Augustine T, Dayan Y, et al. Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer[J]. Oncotarget, 2017, 8(21): 35138-35153.
|
| [40] |
Babaei A, Soleimanjahi H, Soleimani M, et al. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer[J]. Biochem Pharmacol, 2021, 190: 114644.
|
| [41] |
Parakrama R, Fogel E, Chandy C, et al. Immune characterization of metastatic colorectal cancer patients post reovirus administration[J]. BMC Cancer, 2020, 20(1): 569.
|
| [42] |
Jonker DJ, Tang PA, Kennecke H, et al. A randomized phase Ⅱ study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND.210, a Canadian Cancer Trials Group trial[J]. Clin Colorectal Cancer, 2018, 17(3): 231-239, e7.
|